BBOT today
$2.56+$0.36 (+16.36%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $4.15
Key levels
Resistance$3.79
Resistance$2.95
Support$2.51
Latest news & SEC filings
AnalystAnalysts lower BridgeBio Oncology forecasts following Q3 results
AnalystPiper Sandler keeps Overweight on BridgeBio Oncology, cuts target to $15
AnalystWedbush keeps Outperform rating on BridgeBio Oncology, cuts target to $9
All BBOT news →About BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company that develops small molecule drugs aimed at treating cancer. Its pipeline consists of several oral product candidates under clinical evaluation for various tumor types. The company serves patients and healthcare providers, and its operations are based in the United States.
Based on the company's 10-K filed Mar 5, 2026.
Nasdaq · Healthcare
BridgeBio Oncology Therapeutics, Inc. (BBOT)
What Is the Price Target for BBOT?
SEPT Low Target
$9.00
SEPT Mid Target
$15.50
SEPT High Target
$22.00
Analyst Consensus
$15.50
Is BBOT a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BBOT.
Start Free Trial →Is BBOT Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$14.21
12
Moat Score
NONE
4/9
Piotroski Score
0.0
Altman Z-Score
What Is Smart Money Doing with BBOT?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Cobo Marc | officer | Sale | 203 | $544.04 | Oct 21, 2026 |
| Cobo Marc | officer | Sale | 126 | $496.44 | Oct 1, 2026 |
| Elmelech Idan | officer | Sale | 343 | $1K | Oct 1, 2026 |
| Beltran Pedro | director officer | Sale | 1,047 | $4K | Oct 1, 2026 |
| Ben Yong | officer | Sale | 1,047 | $4K | Oct 1, 2026 |
| Cobo Marc | officer | Buy | 9,038 | - | Sep 10, 2026 |
| Cobo Marc | officer | Sale | 203 | $1K | Sep 10, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →BBOT Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
99.93%
FCF Growth YoY
-107.9%
Revenue Trend
UNKNOWN
Dark Pool Trades for BBOT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for BBOT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 09:01:19 | $2.67 | 1,126 | $$3K | BUY |
| 09:00:03 | $2.52 | 1,426 | $$4K | SELL |
| 20:59:56 | $2.56 | 2,200 | $$6K | MIDPOINT |
| 20:58:45 | $2.54 | 1,322 | $$3K | MIDPOINT |
| 20:58:45 | $2.54 | 1,874 | $$5K | MIDPOINT |
5 dark pool trades shown · $$20K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for BridgeBio Oncology Therapeutics, Inc. (BBOT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BBOT — frequently asked questions
What is BBOT stock price today?
BridgeBio Oncology Therapeutics, Inc. (BBOT) is at $2.56, up 16.36% (+$0.36) at the Nov 11, 2026 close.
Why is BBOT stock up today?
Nov 11, 2026: BridgeBio Oncology (BBOT) shares closed at $2.56, up 9.87% on volume of 1,422,891, despite a wave of bearish analyst actions following the company's Q3 2026 financial results. Piper Sandler maintained its Overweight rating but cut its price target to $15, while Wedbush kept an Outperform rating and lowered its target to $9.
What is the BBOT price target?
The average analyst price target for BBOT is $15.50, ranging from $9 to $22, based on 8 analysts. Latest: Wedbush maintains on Nov 11, 2026.
What do analysts rate BBOT?
Analyst ratings for BBOT: 0 Buy, 12 Hold, 0 Sell — consensus Hold.
Did BBOT beat earnings?
BBOT last reported on Nov 11, 2026: EPS -$0.43 vs -$0.69 expected — a beat of 37.7%.
Does BBOT pay a dividend?
BBOT does not currently pay a dividend.
What are BBOT support and resistance levels?
Support: $2.51. Resistance: $2.95, $3.79, $4.15.
What are insiders doing with BBOT?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on BBOT?
Nov 11, 2026: Analysts lower BridgeBio Oncology forecasts following Q3 results · Nov 11, 2026: Piper Sandler keeps Overweight on BridgeBio Oncology, cuts target to $15 · Nov 11, 2026: Wedbush keeps Outperform rating on BridgeBio Oncology, cuts target to $9